Growing prevalence of stomach cancer is expected to drive the growth of global stomach cancer treatment in the forecast period, 2024-2028.
According to TechSci Research report, “Stomach Cancer Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F”, the global stomach cancer treatment market is anticipated to grow at an impressive rate in the forecast period, 2024-2028. This can be ascribed to unhealthy lifestyle changes which also incorporates smoking and alcoholism, etc., globally. Additionally, growing number of cancer treatments centers with successful treatment plans, especially in the developed countries in North America and Europe, are expected to create lucrative opportunities for the market growth in coming years. Besides, increasing research and development activities on cancer is further expected to support the market growth. Similarly, growing approval and subsequent launches of new drugs will further boost the market growth during the forecast period. Also, rapid adoption of advanced diagnostic tools for the early detection of stomach cancer is expected to create a significant growth during the forecast period. Additionally, many pharmaceutical companies are investing for research and development of novel drugs for the treatment of novel drugs and many biosimilars of trastuzumab are entering the market which will further boost the market growth during the forecast period.
However, high cancer therapy cost and less commercial availability of drugs for the treatment of stomach cancer may slow down the growth of global stomach cancer treatment market in the forecast period. Similarly, high risks and complications associated with cancer therapy and treatments, may hamper the global stomach cancer therapy treatment market growth during the forecast period. Also, poor reimbursement scenario and lack of insurance coverage for cancer therapy in emerging countries, can further restrict the growth of global stomach cancer treatment market. Similarly, lesser adoption of targeted therapy because of high costs may hamper the growth of the global stomach cancer treatment market during the forecast period.
Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on “Stomach Cancer Treatment Market“
The global stomach cancer treatment market can be segmented by treatment type, by cancer type, by route of administration, by drug class, by distribution channel and by region.
Based on treatment type, the global stomach cancer treatment market can be segmented into Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others. The immunotherapy segment dominated the market in 2022 and is expected to continue maintaining its dominance throughout the forecast period. This can be ascribed to increasing product launches and new therapies along with growing advancement in cancer treatment such as the development of new radiation therapies for the treatment.
Based on distribution channel, the market can be segmented into Hospital Pharmacies, Specialty Pharmacies, Others. The hospital pharmacies segment is expected to dominate during the forecast period on account of increasing number of patient suffering from stomach cancer in the developing countries.
Major companies operating in global stomach cancer treatment market are:
- Pfizer, Inc.
- Novartis International AG
- Eli Lilly and Company
- Bristol Myers Squibb Company
- Teva Pharmaceutical Industries AG
- F. Hoffmann La Roche AG
- Mylan N.V.
- Celltrion Healthcare Co., Ltd
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
For instance, in April 2021, the FDA approved Opdivo for the initial treatment of patients with metastatic or advanced GC/GEJC. In January 2021, FDA approved Enhertu, an antibody-drug conjugate product for treating HER-2 positive metastatic gastric cancers.
For instance, in August 2019, Taiho Pharmaceutical Co., Ltd. obtained additional indication of unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy for its anticancer agent LONSURF which is an oral anticancer drug used as a combination of trifluridine (antineoplastic nucleoside analogue) and tipiracil (a thymidine phosphorylase inhibitor), from the Japanese Ministry of Health, Labor and Welfare.
Customers can also request for 10% free customization on this report.
“North America is expected to dominate in the global stomach cancer treatment market due to increasing investments in developing advanced treatment options for cancer among the population, . Furthermore, increasing target patient population with untreated diseases, along with different cancer types like stomach cancer are further contributing towards rising stomach cancer treatment demands. Besides, the growing prevalence of adenocarcinoma, lymphoma and gastrointestinal stromal tumors across the globe, the launch of novel therapies for metastatic stomach cancer, availability of skilled professionals and early adoption of advanced treatments for the treatment of stomach cancer in the region is further expected to create lucrative opportunities for the market growth” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Stomach Cancer Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others), By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors), By Route of Administration (Oral v/s Injectables), By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Others), By Region and Competition”, has evaluated the future growth potential of global stomach cancer treatment market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global stomach cancer treatment market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com
